 BOSTON, Sept. 21, 2022 GLOBE NEWSWIRE -- Sensei Biotherapeutics, Inc. Nasdaq: SNSE, an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA V-domain Ig suppressor of T cell activation, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 28 October 1, 2022 at the New York Hilton Midtown in New York, New York. 